This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Rodriguez-Vida A, Saggese M, Hughes S, Rudman S, Chowdhury S, Smith NR, et al. Complexity of FGFR signalling in metastatic urothelial cancer. J Hematol Oncol. 2015; 8: 119. 10.1186/s13045-015-0221-6.Rodriguez-VidaASaggeseMHughesSRudmanSChowdhurySSmithNRComplexity of FGFR signalling in metastatic urothelial cancerJ Hematol Oncol.2015811910.1186/s13045-015-0221-6Open DOISearch in Google Scholar
Knowles MA, Hurst CD. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015; 15(1): 25-41.KnowlesMAHurstCD.Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversityNat Rev Cancer.2015151254110.1038/nrc3817Search in Google Scholar
Li H-T, Duymich CE, Weisenberger DJ, Liang G. Genetic and epigenetic alterations in bladder cancer. Inter Neurourol J. 2016; 20 (Suppl 2): S84-S94.LiH-TDuymichCEWeisenbergerDJLiangG.Genetic and epigenetic alterations in bladder cancerInter Neurourol J.201620suppl 2S84S9410.5213/inj.1632752.376Search in Google Scholar
Nagata M, Muto S, Horie S. Molecular biomarkers in bladder cancer: Novel potential indicators of prognosis and treatment outcomes. Dis Markers. 2016; 2016: 8205836. 10.1155/2016/8205836.NagataMMutoSHorieS.Molecular biomarkers in bladder cancer: Novel potential indicators of prognosis and treatment outcomesDis Markers.20162016820583610.1155/2016/8205836Open DOISearch in Google Scholar
Martin GS. Cell signaling and cancer. Cancer Cell. 2003; 4(3): 167-174.MartinGS.Cell signaling and cancerCancer Cell.20034316717410.1016/S1535-6108(03)00216-2Search in Google Scholar
Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. WIREs Dev Biol. 2015; 4(3): 215-266.OrnitzDMItohN.The fibroblast growth factor signaling pathwayWIREs Dev Biol.20154321526610.1002/wdev.176Search in Google Scholar
Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437(2): 199-213.WescheJHaglundKHaugstenEM.Fibroblast growth factors and their receptors in cancerBiochem J.2011437219921310.1042/BJ20101603Search in Google Scholar
di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: Past, present, and future challenges. Adv Urol. 2012; 2012: 429213. 10.1155/2012/429213.di MartinoETomlinsonDCKnowlesMA.A decade of FGF receptor research in bladder cancer: Past, present, and future challengesAdv Urol.2012201242921310.1155/2012/429213Open DOISearch in Google Scholar
Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho do Y, et al. Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma. Yonsei Med J. 2016; 57(4): 831-839.LimSKohMJJeongHJChoNHChoiYDCho doYFibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinomaYonsei Med J.201657483183910.3349/ymj.2016.57.4.831Search in Google Scholar
Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 2014; 25(3): 552-563.DienstmannRRodonJPratAPerez-GarciaJAdamoBFelipEGenomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumorsAnn Oncol.201425355256310.1093/annonc/mdt419Search in Google Scholar
Wang Z, Zhang C, Sun L, Liang J, Liu X, Li G, et al. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. Oncotarget. 2016; 7(51):98587-84593.WangZZhangCSunLLiangJLiuXLiGFGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patientsOncotarget.2016751985878459310.18632/oncotarget.13139Search in Google Scholar
Yashiro M, Matsuoka T. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer. World J Gastroenterol. 2016; 22(8): 2415-2423.YashiroMMatsuokaT.Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancerWorld J Gastroenterol.20162282415242310.3748/wjg.v22.i8.2415Search in Google Scholar
Theelen WS, Mittempergher L, Willems SM, Bosma AJ, Peters DD, van der Noort V, et al. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer. J Pathol Clin Res. 2016; 2(4): 223-233.TheelenWSMittempergherLWillemsSMBosmaAJPetersDDvan der NoortVFGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancerJ Pathol Clin Res.20162422323310.1002/cjp2.51Search in Google Scholar
Yan J, Jingbo C, Wang D, Xie S, Yuan L, Zhong X, et al. A correlation between decreased parathyroid alpha-Klotho and fibroblast growth factor receptor 1 expression with pathological category and parathyroid gland volume in dialysis patients. Inter Urol Nephrol. 2015; 47(4): 701-706.YanJJingboCWangDXieSYuanLZhongXA correlation between decreased parathyroid alpha-Klotho and fibroblast growth factor receptor 1 expression with pathological category and parathyroid gland volume in dialysis patientsInter Urol Nephrol.201547470170610.1007/s11255-015-0917-0Search in Google Scholar
Serizawa RR, Ralfkiær U, Steven K, Lam GW, Schmiedel S, Schüz J, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Inter J Cancer. 2011; 129(1): 78-87.SerizawaRRRalfkiærUStevenKLamGWSchmiedelSSchüzJIntegrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation eventsInter J Cancer.20111291788710.1002/ijc.25651Search in Google Scholar
Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010; 5(11): e13821.KompierLCLurkinIvan der AaMNvan RhijnBWvan der KwastTHZwarthoffEC.FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapyPLoS One.2010511e1382110.1371/journal.pone.0013821Search in Google Scholar
Juanpere N, Agell L, Lorenzo M, De Muga S, Lopez-Vilaro L, Murillo R, et al. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol. 2012; 43(10): 1573-1582.JuanpereNAgellLLorenzoMDe MugaSLopez-VilaroLMurilloRMutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancerHum Pathol.201243101573158210.1016/j.humpath.2011.10.026Search in Google Scholar
Abdul-Maksoud RS, Shalaby SM, Elsayed WS, Elkady S. Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer. Gene. 2016; 591(2): 320-326.Abdul-MaksoudRSShalabySMElsayedWSElkadyS.Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancerGene.2016591232032610.1016/j.gene.2016.05.043Search in Google Scholar
Sung JY, Sun JM, Chang Jeong B, Il Seo S, Soo Jeon S, Moo Lee H, et al. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol Oncol. 2014; 32(1): 49.e23-e31.SungJYSunJMChang JeongBIl SeoSSoo JeonSMoo LeeHFGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapyUrol Oncol.201432149e23e3110.1016/j.urolonc.2013.07.015Search in Google Scholar
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014; 3(4): 835-844.GuancialEAWernerLBellmuntJBamiasAChoueiriTKRossRFGFR3 expression in primary and metastatic urothelial carcinoma of the bladderCancer Med.20143483584410.1002/cam4.262Search in Google Scholar
Bertz S, Abee C, Schwarz-Furlan S, Alfer J, Hofstadter F, Stoehr R, et al. Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer. Virchows Archiv. 2014; 465(6): 687-695.BertzSAbeeCSchwarz-FurlanSAlferJHofstadterFStoehrRIncreased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancerVirchows Archiv.2014465668769510.1007/s00428-014-1672-9Search in Google Scholar
Ahmad I, Iwata T, Leung HY. Mechanisms of FG-FR-mediated carcinogenesis. Biochim Biophys Acta. 2012; 1823(4): 850-860.AhmadIIwataTLeungHY.Mechanisms of FG-FR-mediated carcinogenesisBiochim Biophys Acta.20121823485086010.1016/j.bbamcr.2012.01.004Search in Google Scholar
Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol. 2011; 9(1): 41-51.NettoGJ.Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?Nat Rev Urol.201191415110.1038/nrurol.2011.193Search in Google Scholar
Fischbach A, Rogler A, Erber R, Stoehr R, Poulsom R, Heidenreich A, et al. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathol. 2015; 66(5): 639-649.FischbachARoglerAErberRStoehrRPoulsomRHeidenreichAFibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancerHistopathol.201566563964910.1111/his.12473Search in Google Scholar
Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF
receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Brit J Cancer. 2011; 104(1): 75-82.LamontFRTomlinsonDCCooperPAShnyderSDChesterJDKnowlesMA.Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivoBrit J Cancer.20111041758210.1038/sj.bjc.6606016Search in Google Scholar
Maeng YH, Eun SY, Huh JS. Expression of fibroblast growth factor receptor 3 in the recurrence of nonmuscle-invasive urothelial carcinoma of the bladder. Korean J Urol. 2010; 51(2): 94-100.MaengYHEunSYHuhJS.Expression of fibroblast growth factor receptor 3 in the recurrence of nonmuscle-invasive urothelial carcinoma of the bladderKorean J Urol.20105129410010.4111/kju.2010.51.2.94Search in Google Scholar
Choi CH, Chung JY, Kim JH, Kim BG, Hewitt SM. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. J Transl Med. 2016; 14(1): 124.ChoiCHChungJYKimJHKimBGHewittSM.Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patientsJ Transl Med.201614112410.1186/s12967-016-0874-0Search in Google Scholar
Zhou W, Du X, Song F, Zheng H, Chen K, Zhang W, et al. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor. Oncotarget. 2016; 7(16): 22234-22244.ZhouWDuXSongFZhengHChenKZhangWPrognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumorOncotarget.2016716222342224410.18632/oncotarget.8067Search in Google Scholar
Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: Implications for therapeutic targeting. PLoS One. 2013; 8(2): e57284.ChengTRothBChoiWBlackPCDinneyCMcConkeyDJ.Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: Implications for therapeutic targetingPLoS One.201382e5728410.1371/journal.pone.0057284Search in Google Scholar
Chen Y, Xie X, Li X, Wang P, Jing Q, Yue J, et al. FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell. Biochem Biophys Res Commun. 2016; 474(1): 1-7.ChenYXieXLiXWangPJingQYueJFGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cellBiochem Biophys Res Commun.201647411710.1016/j.bbrc.2016.03.017Search in Google Scholar
Tomlinson DC, Knowles MA. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol. 2010; 177(5): 2379-2386.TomlinsonDCKnowlesMA.Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancerAm J Pathol.201017752379238610.2353/ajpath.2010.100354Search in Google Scholar
Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity (Edinb). 2010; 105(1): 4-13.GibneyERNolanCM.Epigenetics and gene expressionHeredity (Edinb).2010105141310.1038/hdy.2010.54Search in Google Scholar
